Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Ligand Pharmaceuticals's cash was $447.40M at Sep 30, 2026. For fiscal 2025 it was $733.52M, up 186.3% from the year before. Over ten years it grew 13.9% a year on average. The highest annual figure on record is $1.07B in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $733.52M | +186.3% |
| FY2024 | Dec 31, 2024 | $256.17M | +50.4% |
| FY2023 | Dec 31, 2023 | $170.31M | -19.6% |
| FY2022 | Dec 31, 2022 | $211.87M | -37.9% |
| FY2021 | Dec 31, 2021 | $341.11M | -17.1% |
| FY2020 | Dec 31, 2020 | $411.53M | -61.6% |
| FY2019 | Dec 31, 2019 | $1.07B | +48.5% |
| FY2018 | Dec 31, 2018 | $721.00M | +257.5% |
| FY2017 | Dec 31, 2017 | $201.66M | +43.0% |
| FY2016 | Dec 31, 2016 | $141.05M | -29.6% |
| FY2015 | Dec 31, 2015 | $200.22M | +19.7% |
| FY2014 | Dec 31, 2014 | $167.34M | +947.2% |
| FY2013 | Dec 31, 2013 | $15.98M | +29.1% |
| FY2012 | Dec 31, 2012 | $12.38M | -27.3% |
| FY2011 | Dec 31, 2011 | $17.04M | -24.9% |
| FY2010 | Dec 31, 2010 | $22.70M | +41.6% |
| FY2009 | Dec 31, 2009 | $16.03M | -44.2% |
| FY2008 | Dec 31, 2008 | $28.75M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $447.40M | -32.7% |
| Q2 FY2026 | Jun 30, 2026 | $1.36B | +454.1% |
| Q1 FY2026 | Mar 31, 2026 | $779.41M | +273.1% |
| Q4 FY2025 | Dec 31, 2025 | $733.52M | +186.3% |
| Q3 FY2025 | Sep 30, 2025 | $664.52M | +202.5% |
| Q2 FY2025 | Jun 30, 2025 | $245.02M | +8.0% |
| Q1 FY2025 | Mar 31, 2025 | $208.90M | -32.7% |
| Q4 FY2024 | Dec 31, 2024 | $256.17M | +50.4% |
| Q3 FY2024 | Sep 30, 2024 | $219.64M | +14.9% |
| Q2 FY2024 | Jun 30, 2024 | $226.93M | +3.6% |
| Q1 FY2024 | Mar 31, 2024 | $310.59M | +9.9% |
| Q4 FY2023 | Dec 31, 2023 | $170.31M | -19.6% |
| Q3 FY2023 | Sep 30, 2023 | $191.09M | +57.4% |
| Q2 FY2023 | Jun 30, 2023 | $219.04M | +48.1% |
| Q1 FY2023 | Mar 31, 2023 | $282.67M | +38.6% |
| Q4 FY2022 | Dec 31, 2022 | $211.87M | -37.9% |
| Q3 FY2022 | Sep 30, 2022 | $121.41M | -62.4% |
| Q2 FY2022 | Jun 30, 2022 | $147.94M | -51.0% |
| Q1 FY2022 | Mar 31, 2022 | $204.00M | -39.9% |
| Q4 FY2021 | Dec 31, 2021 | $341.11M | -17.1% |
| Q3 FY2021 | Sep 30, 2021 | $323.21M | -59.4% |
| Q2 FY2021 | Jun 30, 2021 | $301.98M | -62.7% |
| Q1 FY2021 | Mar 31, 2021 | $339.55M | -54.1% |
| Q4 FY2020 | Dec 31, 2020 | $411.53M | -61.6% |
| Q3 FY2020 | Sep 30, 2020 | $795.26M | -27.7% |
| Q2 FY2020 | Jun 30, 2020 | $810.61M | -39.2% |
| Q1 FY2020 | Mar 31, 2020 | $739.54M | -48.3% |
| Q4 FY2019 | Dec 31, 2019 | $1.07B | +48.5% |
| Q3 FY2019 | Sep 30, 2019 | $1.10B | +4.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.33B | +39.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.43B | +441.3% |
| Q4 FY2018 | Dec 31, 2018 | $721.00M | +257.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.05B | +419.3% |
| Q2 FY2018 | Jun 30, 2018 | $956.93M | +454.3% |
| Q1 FY2018 | Mar 31, 2018 | $264.35M | +65.9% |
| Q4 FY2017 | Dec 31, 2017 | $201.66M | +43.0% |
| Q3 FY2017 | Sep 30, 2017 | $202.26M | – |
| Q2 FY2017 | Jun 30, 2017 | $172.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $159.37M | – |
| Q4 FY2016 | Dec 31, 2016 | $141.05M | – |
See a number that looks wrong?